afreza, an inhalable diabetes treatment developed by california-based mankind got backing from a fda panel for type one and type two diabetes today. the inhaler, which can fit in your palm, is meant to be a more convenient, less painful alternative to injections. >> we heard over and over again how difficult the times diabetics have controlling their disease. and why we need new tools and better tools. >> reporter: despite today's win, afreza still has a way to go before becoming available to patients. the treatment still needs fda approval and a partner to commercially launch the drug. perhaps most importantly, it still needs to win over patients and doctors. >> in the treatment of diabetes and obesity, what we see is a market that is built on years of foundation. because of that it can be very difficult to move. there's a lot of inertia in the practices. >> reporter: afreza isn't the first to develop an inhalable version of insulin. pfizer released its own version no in 2006. critics say the inhaler was bulky there were concerns about dosing requirements and marketing wasn't enough